Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al
Case Number:
1:19-cv-00203
Court:
Nature of Suit:
835(Patent - Abbreviated New Drug Applications (ANDA))
Judge:
District Judge John Preston Bailey
Firms
Companies
Sectors & Industries:
-
November 10, 2022
Viatris Sways Judge To Ax AstraZeneca Inhaler Patent
A West Virginia federal judge has granted drugmaker Viatris' bid to invalidate one of rival AstraZeneca's patents on brand name asthma treatment Symbicort, determining that the challenged claims are invalid for lack of enablement and lack of written description.
-
March 03, 2021
AstraZeneca Beats Mylan Challenge To Inhaler IP's Validity
AstraZeneca scored a win in a suit accusing Mylan Pharmaceuticals of infringing patents for its asthma treatment Symbicort when a West Virginia federal judge on Tuesday shot down arguments that the patents were invalid.